Collaborations to commercialize oncology biosimilars

INICIO/Noticias Farmacéuticas | Posted 22/10/2021 post-comment0 Post your comment

New collaborations to commercialize oncology biosimilars have been announced between Sandoz and Bio-Thera Solutions, and between Innovent Biologics and Ascentage Pharma.

Cancer Cell V13I20

Sandoz – Bio-Thera Solutions collaboration
On 8 September 2021, Sandoz announced its agreement with China-based Bio-Thera Solutions (Bio-Thera) to commercialize the latter’s bevacizumab oncology biosimilar, BAT1706.

Bio-Thera had submitted an application for its proposed bevacizumab biosimilar, BAT1706, to the European Medicines Agency on 25 November 2020 [1]; whilst the US Food and Drug Administration had accepted the Biologics License Application for its proposed bevacizumab biosimilar, BAT1706, in January 2021 [2].

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor alpha (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers, including colorectal, lung, breast, glioblastoma, kidney and ovarian [3].

Bevacizumab is commonly used in combination with other treatments. The originator drug product is Genentech’s (now part of Roche) cancer medicine, Avastin, which had 2016 sales of CHF 6.8 billion (Euros 5.95 billion) before the advent of biosimilars.

Under the terms of the agreement, Bio-Thera Solutions, will maintain responsibility for development and manufacturing, Sandoz will have the right to commercialize the medicine following approval in the US, Europe, Canada and other selected countries. In addition, Bio-Thera Solutions will receive an upfront and milestone payments and is entitled to receive profit share payments.

The agreement sees Sandoz adding to its biosimilars and generics portfolio of over 50 products.

On 24 August 2020, Bio-Thera and BeiGene entered into a license, distribution and supply agreement for BAT1706 in China [4].

Innovent Biologics – Ascentage Pharma collaboration
In July 2021, Innovent and Ascentage announced a multifaceted strategic collaboration. This includes the joint commercialization of Ascentage’s China developed olverembatinib leukaemia biosimilar in China, together with the collaborative clinical development of an additional biosimilar (HALPRYZA®, a rituximab biosimilar injection) and a novel oncology medicine (lisaftoclax). Innovent also made an equity investment of US$30 million in Ascentage, and the latter will be eligible to receive up to US$115 if certain pre-specified milestones in development, registration and annual sales performance of the olverembatinib biosimilar are met. Profits from the commercialization agreement will be split equally.

Back in June 2020, China’s National Medical Products Administration approved Innovent’s copy biological IBI305, Byvasda [5] to be used in combination with its TYVYT (Sintilimab), positive phase III results were reported on 23 November 2020 [6].

Related articles
Bevacizumab biosimilars launched in Spain and Korea

Clinical development of biosimilars in the oncology setting

Innovent makes deal for bevacizumab copy biological in Indonesia

Innovent starts phase II trial for ipilimumab copy biological

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Grupos de gastroenterólogos argentinos emiten su posicionamiento sobre el uso de biosimilares

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Grupos de gastroenterólogos argentinos emiten su posicionamiento sobre el uso de biosimilares

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA accepts application for bevacizumab biosimilar BAT1706 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 22]. Available from: www.gabionline.net/biosimilars/news/EMA-accepts-application-for-bevacizumab-biosimilar-BAT170
2. GaBI Online - Generics and Biosimilars Initiative. FDA accepts application for bevacizumab biosimilar BAT1706 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 22]. Available from: www.gabionline.net/biosimilars/news/FDA-accepts-application-for-bevacizumab-biosimilar-BAT1706
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 22]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-bevacizumab
4. GaBI Online - Generics and Biosimilars Initiative. Bio-Thera and BeiGene sign deal to license, distribute and supply Avastin copy biological BAT1706 in China [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 22]. Available from: www.gabionline.net/pharma-news/Bio-Thera-and-BeiGene-sign-deal-to-license-distribute-and-supply-Avastin-copy-biological-BAT1706-in-China
5. GaBI Online - Generics and Biosimilars Initiative. China approves bevacizumab copy biological Byvasda [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 22]. Available from: www.gabionline.net/biosimilars/news/China-approves-bevacizumab-copy-biological-Byvasda
6. GaBI Online - Generics and Biosimilars Initiative. Positive phase III results for sintilimab plus copy biological [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 22]. Available from: www.gabionline.net/biosimilars/research/Positive-phase-III-results-for-sintilimab-plus-copy-biological-Byvasda

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Spinoff updates: Merck’s Organon and Novartis’ Sandoz
24 AA011041
INICIO/Noticias Farmacéuticas Posted 26/11/2021
Swiss Social Democrat’s for nationalization of Sandoz
28 MD002360
INICIO/Noticias Farmacéuticas Posted 19/11/2021
Ustekinumab biosimilars: new international biopharma agreements
Contract Tender V13H30
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Biocon Biologics and Serum Institute Life Sciences partnership
64 MD002129
INICIO/Noticias Farmacéuticas Posted 12/11/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010